• 1
    Wild C, Vineis P, Garte S, eds. Molecular Epidemiology of Chronic Diseases. Chicester: Wiley, 2008.
  • 2
    Vineis P. Individual susceptibility to carcinogens. Oncogene 2004;23:647783.
  • 3
    Bonassi S, Au WW. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res 2002;511:7386.
  • 4
    Milikan R. The changing face of epidemiology in the genomics era. Epidemiology 2002;13:47280.
  • 5
    Hunter DJ. The future of molecular epidemiology. Int J Epidemiol 1999;28:S10124.
  • 6
    Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005;14:1899907.
  • 7
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:11804.
  • 8
    Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43:255979.
  • 9
    Blair A, Saracci R, Vineis P, Cocco P, Forastiere F, Grandjean P et al. Epidemiology, public health and the rhetoric of false positives. Environ Health Perspect 2009;117:180913.
  • 10
    Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;14:104355.
  • 11
    Ioannidis JPA, Panagiotou O. Comparison of effect sizes of biomarkers reported in highly-cited articles versus subsequent meta-analyses. JAMA 2011;305:220010.
  • 12
    Lumbreras B, Parker LA, Porta M, Pollan M, Ioannidis JP, Hernandez-Aguado I. Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem 2009;55:78694.
  • 13
    Ioannidis JP, Tarone R, McLaughlin JK. The False-positive to False-negative ratio in epidemiologic studies. Epidemiology 2011, 22, 4506.
  • 14
    Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010;7:e1000251.
  • 15
    Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included insystematic reviews. BMC Med Res Methodol 2003;3:25.
  • 16
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
  • 17
    Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297. Review.
  • 18
    Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology 2009;116:28696.
  • 19
    Da Costa B, Cevallos M, Altman D, Rutjes AW, Egger M. Uses and misuses of the STROBE statement: bibliographic study. BMJ 2010, Open doi:10.1136/bmjopen-2010-000048.
  • 20
    Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E et al. Strengthening the reporting of genetic association studies (STREGA)-an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol 2009;62:597608.
  • 21
    Casteleyn L, Dumez B, Jamers A, Van Damme K. Ethics and data protection in human biomarker studies. ECNIS Publications, Lodz, 2010.
  • 22
    Haines DA, Arbuckle TE, Lye E, Legrand M, Fisher M, Langlois R et al. Reporting results of human biomonitoring of environmental chemicals to study participants: a comparison of approaches followed in two Canadian studies. J Epidemiol Community Health 2011;65:1918.
  • 23
    Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:30914.
  • 24
    Porta M, ed. A Dictionary of Epidemiology, 5th Edn. New York: Oxford University Press, 2008. P. 21, 69, 129-130, 152, 157–158.
  • 25
    Porta M, Pumarega J, López T, Jariod M, Marco E, Grimalt JO. Influence of tumor stage, symptoms and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Cancer Causes Control 2009;20:1893906.
  • 26
    Porta M, Pumarega J, Ferrer-Armengou O, López T, Alguacil J, Malats N et al. Timing of blood extraction in epidemiologic and proteomic studies. Results and proposals from the PANKRAS II Study. Eur J Epidemiol 2007;22:57788.
  • 27
    Ruchirawa M, Mahidol C, Tangjarukij C, Pui-ock S, Jensen O, Kampeerawipakorn O et al. Exposure to genotoxins present in ambient air in Bangkok, Thailand – particle associated polycyclic aromatic hydrocarbons and biomarkers. Sci Total Environ 2002;287:12132.
  • 28
    Sorensen M, Autrup H, Hertel O, Wallin H, Knudsen LE, Loft S. Personal exposure to PM2.5 and biomarkers of DNA damage. Cancer Epidemiol Biomarkers Prev 2003;12:1916.
  • 29
    Dusinska M, Vallova B, Ursinyova M, Hladikova V, Smolkova B, Wsolova L et al. DNA damage and antioxidants; fluctuations through the year in a central European population group. Food Chem Toxicol 2002;40:111923.
  • 30
    Giovannelli L, Saieva C, Masala G, Testa G, Salvini S, Pitozzi V et al. Nutritional and lifestyle determinants of DNA oxidative damage: a study in a Mediterranean population. Carcinogenesis 2002;23:1483.
  • 31
    Moller P, Wallin H, Holst E, Knudsen LE. Sunlight-induced DNA damage in human mononuclear cells. FASEB J 2002;16:4553.
  • 32
    Ioannidis JPA. Genetic and molecular epidemiology. J Epidemiol Community Health 2007;61:7578.
  • 33
    Phillips DH, Castegnaro M. Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 1999;14:301.
  • 34
    Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010;11:7339.
  • 35
    Castaldi PJ, Dahabreh IJ, Ioannidis JP. An empirical assessment of validation practices for molecular classifiers. Brief Bioinform 2011;12:189202. Epub 2011 Feb 7.
  • 36
    Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;4:45373.
  • 37
    Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 2002;11:15449.
  • 38
    Vainio H. Genetic biomarkers and occupational epidemiology –recollections, reflections and reconsiderations. Scand J Work Environ Health 2004;30:13.
  • 39
    Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. 2010. PLoS Med 2010;7:e1000217.
  • 40
    Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for reporting health research: the EQUATOR network’s survey of guideline authors. PLoS Med 2008;5:e139.
  • 41
    Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:3553.
  • 42
    Vineis P, Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 2007;16:195465.
  • 43
    Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:8995.
  • 44
    Decordier I, VandeLoock K, Kirsch-Volders M. Phenotyping for DNA repair capacity. Mutat Res 2010;705:10729.
  • 45
    Ioannidis JP, Tzoulaki I. What makes a good predictor? the evidence applied to coronary artery calcium score. JAMA 2010;16:16467.
  • 46
    Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009;100:121929.
  • 47
    Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP. New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. Pancreas 2011;40:52232.
  • 48
    Gallo V, Khan A, Gonzales C, Phillips DH, Schoket B, Győrffy E et al. Validation of biomarkers for the study of environmental carcinogens: a review. Biomarkers 2008;13:50534.
  • 49
    Vineis P, Gallo V. Epidemiological Concepts of Validation of Biomarkers for the Identification/Quantification of Environmental Carcinogenic Exposures. Poland: ECNIS; 2007.
  • 50
    Vineis P, Matullo G, Berwick M. Molecular epidemiology. In: Ahrens W, Pigeot I, editors. Handbook of Epidemiology. Berlin & Heidelberg: Springer, 2005:111138.
  • 51
    Kristensen P. Bias from nondifferential but dependent misclassification of exposure and outcome. Epidemiology 1992;3:2105.
  • 52
    Vineis P. Sources of variation in biomarkers. IARC Sci Publ 1997;142:5971.
  • 53
    Vahakangas K. Ethical aspects of molecular epidemiology of cancer. Carcinogenesis 2004;25:46571.